IRIS
ALONCI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.667
EU - Europa 2.110
AS - Asia 684
OC - Oceania 9
SA - Sud America 4
AF - Africa 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.476
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.652
IE - Irlanda 621
SE - Svezia 582
CN - Cina 337
SG - Singapore 297
UA - Ucraina 218
IT - Italia 189
DE - Germania 178
FI - Finlandia 117
GB - Regno Unito 98
BE - Belgio 22
PL - Polonia 20
FR - Francia 19
IN - India 19
AT - Austria 16
CA - Canada 13
IR - Iran 13
NL - Olanda 7
VN - Vietnam 7
AU - Australia 6
RU - Federazione Russa 6
CZ - Repubblica Ceca 5
CH - Svizzera 3
NZ - Nuova Zelanda 3
RO - Romania 3
BR - Brasile 2
CL - Cile 2
HK - Hong Kong 2
ID - Indonesia 2
NO - Norvegia 2
TR - Turchia 2
AM - Armenia 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
IQ - Iraq 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MX - Messico 1
PK - Pakistan 1
PT - Portogallo 1
Totale 5.476
Salva come PNG Salva come JPEG
Città #
Dublin 621
Chandler 562
Jacksonville 450
Nyköping 298
Singapore 240
Beijing 172
Ashburn 133
Dearborn 122
Princeton 109
Cambridge 106
Medford 106
Messina 97
Ann Arbor 90
Des Moines 90
Boardman 76
New York 46
Woodbridge 46
Wilmington 28
Brussels 22
Lancaster 22
Los Angeles 21
Warsaw 20
Shenyang 18
Munich 16
San Mateo 16
Vienna 16
Hebei 15
Jinan 15
Nanjing 14
Tianjin 13
Helsinki 11
Bremen 10
Pune 10
Rome 10
Auburn Hills 9
Seattle 9
Hangzhou 8
Houston 8
Ningbo 8
Washington 8
Milan 7
Strasbourg 7
Zhengzhou 7
Ardabil 6
Augusta 6
Dong Ket 6
Lanzhou 6
Palermo 6
Changsha 5
Falls Church 5
Haikou 5
Hyderabad 5
London 5
Monmouth Junction 5
Ottawa 5
Taiyuan 5
Brno 4
Cosenza 4
Ferrandina 4
Fuzhou 4
Latina 4
Norwalk 4
Chapel Hill 3
Esher 3
Guangzhou 3
Jiaxing 3
Kelowna 3
Lausanne 3
Leawood 3
Redwood City 3
Saint Petersburg 3
Sector 3 3
Civitanova Marche 2
Cordenons 2
Espoo 2
Hefei 2
Hong Kong 2
Indianapolis 2
Jakarta 2
Kunming 2
Modica 2
Montréal 2
Nienhagen 2
Oslo 2
Padova 2
Pescara 2
Rimini 2
Riva 2
San Gregorio d'Ippona 2
Santa Clara 2
Shanghai 2
Tappahannock 2
Ambrolauri 1
Amsterdam 1
Auckland 1
Baotou 1
Berkeley 1
Boston 1
Cairo 1
Chaoyang 1
Totale 3.884
Salva come PNG Salva come JPEG
Nome #
Diagnostic utility of Sudoscan for detecting Bortezomib-induced painful neuropathy 115
Effect of therapeutic plasma exchange on plasma levels of oxidative biomarkers in a patient with thrombotic thrombocytopenic purpura 110
The cancer stem cell hypothesis: a guide to potential molecular targets. 92
L'ipersplenismo: attualità e prospettive future 90
Absence of the V617F JAK2 Mutation in the Lymphoid Compartment in a Patient with Essential Thrombocythemia and B-Chronic Lymphocytic Leukemia and in Two Relatives with Lymphoproliferative Disorders 84
Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws 82
Patients with bisphosphonate-associated osteonecrosis of the jaw have unmodified levels of soluble vascular endothelial growth factor receptor 1. 80
MDR-1 gene polymorphisms G2677T and C3435T in a case of Hodgkin's variant of Richter's syndrome 80
Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors 79
E rosette formation in B cell chronic lymphocytic leukemia. 77
Anticancer Activity of Curcumin and Its Analogues: Preclinical and Clinical Studies 77
Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer. 76
Circulating levels of intercellular adhesion Molecule-1 (ICAM-1) and soluble Interleukin 2 receptors(IL-2R) in patients with B cell Chronic Lynphocityc Leukemia 69
Angiogenesis in patients with biphosphonate-associated osteonecrosis of the jaw 67
Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and n two relatives with lymphoproliferative disorders 67
Beta 2 microglobulina ed emopatie maligne 66
Evaluation of Interleukin-17 serum levels in patients with chronic myeloproliferative diseases. 65
Immunohistochemical evaluation of sarcoglycans and integrin in gingival epithelium of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw 65
Circulating levels of intercellular adhesion molecule-1 (ICAM-1) and soluble interleukin 2 receptors (IL-2R) in patients with B cell chronic lymphocytic leukaemia. 65
Cold pressor test raises serum concentrations of ICAM-1, VCAM- 1, and E-selectin in normotensive and hypertensive patients 64
Assenza della mutazione JAK2 V617F nel compartimento linfoide di un paziente affetto da trombocitemia essenziale e leucemia linfatica cronica a cellule B ed in due parenti affetti da disordini linfoproliferativi 64
Serum levels of soluble ICAM-1 in patients with malignant lymphoma in association with treatment response. 64
Serum levels of interleukin-16 in lymphoid malignancies. 63
Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications 63
Angiogenesis in patients with bisphosphonate-associated osteonecrosis of the jaw. 62
Immunohistochemical evaluation of sarcoglycans and integrins in gingival epithelium of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw. 62
ABERRANT EXPRESSION OF CANCER TESTIS ANTIGENS IN HEMATOLOGIC MALIGNANCIES 61
Circulating microRNAs: New biomarkers in diagnosis, prognosis and treatment of cancer (Review). 61
Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases. 59
Carbonyl groups serum levels are associated with CD38 expression in patients with B chronic lymphocytic leucemia. 59
Elevated srum concentration of angiopoietin-2 in patients with multiple myeloma: correlation with markers of disease 58
Avascular Necrosis of Bone in Leukemia and Osteonecrosis of Jaw by Bisphosphonates 56
Lipid profile in hematologic neoplasms 55
Circulating endothelial progenitor cells and angiogenic serum factors in patients with chronic myeloproliferative diseases 55
MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis. 55
Decreased plasma levels of IL-33 could contribute to the altered function of Th2 Iymphocytes in patients with poIycythemia vera and essential thrombocythemia. 55
Severe dermatologic adverse reactions after exposure to lenalidomide in multiple myeloma patients with a positive HLA-DRB1*1501 and HLA-DQB1*0602. 55
SOLUBLE ANGIOGENIC FACTORS: IMPLICATIONS FOR CHRONIC MYELOPROLIFERATIVE DISORDERS 54
Increase in serum protein carbonyl groups is associated with more advanced stage of disease in multiple myeloma patients. 54
Possible role of Interleuki-31/33 Axis in Imatinib Mesylate-Associated Skin Toxicity 54
MARKERS OF ENDOTHELIAL AND PLATELET STATUS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA AND PLYCYTHEMIA VERA 53
Evaluation des sous-populations lymphocytaires chez des travailleurs exposés a basse dose du benzene. Données préliminaires”. 53
Cardiac involvement in patients with hematologic malignancies. 53
Patients with bisphosphonates-associated osteonecrosis of the jaw have reduced circulating endothelial cells 53
Efficacia di Nilotinib in un giovane paziente affetto da LMC ad alto rischio Sokal in fallimento dopo inatinib ad alte dosi 52
JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease. 51
Interleukin 22 is increased and correlated with CD38 expression in patients with B-chronic lymphocytic leukemia 50
Prognostic value of serum thymidine kinase and beta 2 microglobulin in subjects affected by multiple myeloma 49
METHYMAZOLE-INDUCED AGRANULOCYTOSIS AND QUICK RECOVERY WITH G-CSF: CARE REPORT 48
Serum levels of Interleukin-16 in a multiple myeloma patient with cutaneous involvement 48
Serum levels of 2',5 oligoadenylate synthetase during interferon therapy in patients with B-cell chronic lymphocytic leukemia 48
Increase of IL-17, IL-22 and IL-23 serum levels induced by immunoglobulin infusion for Parvovirus-B associated Pure Red Cell Aplasia in a renal transplant recipient. 48
MULTIDRUG RESISTANCE-1 GENE POLYMORPHISM ASSOCIATED WITH THE NEW MARKER OF DISEASE PROGRESSION AND POOR PROGNOSIS IN b-CELL CHRONIC LIMPHATIC LEUKEMIA 47
Serum levels of CD8 antigen and soluble interleukin 2 receptors in patients with B cell chronic lymphocytic leukemia. 47
Endothelial progenitor cells: pathogenetic role and therapeutic perspectives 47
Epigenetic therapy in myelodysplastic syndromes. 47
Myeloproliferative Disease: Markers of Endothelial and Platelet Status in Patients with Essential Thrombocythemia and Polycythemia Vera. 47
Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options. 47
SERUM LEVELS OF 2', 5 OLIGOADENYLATE SYNTHETASE DURING INTERFERON THERAPY IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC- LEUKEMIA 46
Correlazione del polimorfismo genico di MDR-1 con i nuovi marcatori prognostici in pazienti affetti da Leucemia Linfatica Cronica a cellule B. 46
Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia. 46
Involvement of T2677T multidrug resistance gene polymorphism in Interleukin 22 plasma concentration in B-chronic lymphocytic leukemia patients. 46
Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia 46
Standardisation of minimal residual disease in multiple myeloma 46
Prognostic significance of immunophenotype in chronic lymphocytic leukaemia 45
POLYRADICOLONEUROPATHY AS A FORM OF RELAPSE IN A PATIENT WITH ACUTE MEGACARYOCYTIC LEUKAEMIA 45
EFFECTIVE THERAPY OF APLASTIC-ANEMIA POSTHEPATITIS WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN 45
Monocytes and lymphocytes as active participants in the pathogenesis of experimental shock 45
Association of osteonecrosis of the jaws and POEMS syndrome in a patient assuming rituximab. 45
JAK2-Positive Latent Essential Thrombocythemia and Splanchnic Vein Thrombosis: The Role of Bone Marrow Biopsy for the Diagnosis of Myeloproliferative Disease. 44
Reduced serum levels of interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration 44
Intracellular and serum levels of aldolase activity in B chronic lymphocytic leukemia. 44
Serum levels of interleukin-16 in a multiple myeloma patient with cutaneous involvement. 44
MiRNome expression is deregulated in the peripheral lymphoid compartment of multiple myeloma 43
Serum levels of Interleukin-16 as an important prognostic factor in multiple Myeloma patient with cutaneous involvement 42
Increased levels of the soluble adhesion molecule E-selectin in patients with chronic myeloproliferative disorders and thromboembolic complications 42
Evaluation of circulating endothelial progenitor cells in patients with bisphosphonate-associated osteonecrosis of the jaw 42
Serum levels of soluble ICAM-1 in patients with malignant lymphoma in association with treatment response 41
Reduction in IL-33 Plasma Levels Might Be Involved in T Cell Dysregulation in Chronic Lymphocytic Leukemia. 40
Imatinib mesylate treatment in a patient with chemoresistant Ph+ acute myeloid leukemia: possible role of Wilms' tumor gene 1. 39
SERUM LEVELS OF CD8-ANTIGEN AND SOLUBLE INTERLEUKIN-2 RECEPTORS IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA 38
Increased serum levels of interleukin-31 could modulate inflammatory processes in multiple sclerosis 38
E-ROSETTE FORMATION IN B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA 37
Fludarabine based treatment caused improvement of anemia in a patient with T-cell LGL leukemia despite evidence of the persistence of the abnormal T-cell clone. 37
Soluble CD138 serum levels are not associated with other poor prognostic markers in patients with B-chronic lymphocytic leukaemia. 37
Screening dei deficit di G-6-PD in un campione di una popolazione scolastica 37
INTRACELLULAR AND SERUM LEVELS OF ALDOLASE ACTIVITY IN B- CHRONIC LYMPHOCYTIC-LEUKEMIA 35
Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B. 35
Increased serum levels of neutrophil gelatinase-associated lipocalin in patients with essential thrombocythemia and polycythemia vera. 34
Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. 34
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma. 34
Significance of serum interleukin-16 levels in patients with B-cell chronic lymphocytic leukemia 33
Differential levels of soluble angiopèoietin-2 and Tie-2 in patients with haematological malignancies 33
Imatinib mesylate therapy induces reduction in neutrophil gelatinase-associated lipocalin serum levels and increase in leptin concentrations in chronic myeloid leukemia patients in molecular remission. 33
Soluble angiogenic factors: Implications for chronic myeloproliferative disorders 31
null 31
Levels of soluble angiogenin in chronic myeloid malignancies: clinical implications 30
Serum levels of angiopoietin-2 and its receptor TIE2 in Chronic myeloproliferative disease 30
Increase of novel biomarkers for oxidative stress in patients with plasma cell disorders and in multiple myeloma patients with bone lesions. 30
Leukocyte integrin very late antigen-4/vascular cell adhesion molecule-1 adhesion pathway in splanchnic artery occlusion shock 29
Totale 5.269
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.838
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.838
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020598 0 0 0 0 0 116 122 83 10 122 141 4
2020/2021706 95 3 125 47 29 92 8 41 41 85 81 59
2021/2022641 5 57 14 20 18 8 40 26 13 89 98 253
2022/20231.944 164 168 82 174 165 199 17 110 775 9 58 23
2023/2024448 39 73 28 35 49 118 20 30 3 11 6 36
2024/2025391 23 27 49 170 79 43 0 0 0 0 0 0
Totale 5.529